It is no longer the current profile. Read the canonical profile and its correction notice.
We added a plain-language reader guide with cited answers, re-checked the Langlara label, and added the Drugs@FDA record and FDA’s April 2026 approval letter. 123
What this version reported
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.↗↗
Reader guide in this version
Key takeaway
Insulin glargine-aldy is a long-acting insulin, sold as Langlara, that FDA licensed on April 29, 2026 to improve blood-sugar control in adults and children with diabetes.1,2,3 FDA’s approval letter describes the application as seeking licensure of Langlara as biosimilar to and interchangeable with US-licensed Lantus (insulin glargine).3 The clinical studies in its label are the insulin glargine studies against NPH insulin, involving thousands of adults and children, not trials run specifically with insulin glargine-aldy.1
At a glance
- What it is
- A long-acting insulin glargine product. The label states that insulin lowers blood sugar by helping muscle and fat take up glucose and by reducing the liver’s glucose output.1
- FDA status
- FDA-approved. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026. The cited label has no boxed warning.1,2
- Human evidence
- Large randomized studies of insulin glargine compared with NPH insulin, summarized in the label; these are not studies of insulin glargine-aldy itself.1
- Evidence strength
- Large randomized human trials
What is insulin glargine-aldy?
Insulin glargine-aldy is an insulin glargine product, a lab-made long-acting form of insulin. Drugs@FDA lists it as Langlara, from Sunshine Lake Pharma, under application BLA761412.1,2
FDA’s approval letter states that the application was submitted under section 351(k) of the Public Health Service Act and describes it as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus.3
How does insulin glargine-aldy work?
The label states that the main action of insulin, including insulin glargine products, is to regulate glucose metabolism.1
According to the label, insulin lowers blood sugar by stimulating glucose uptake, especially by muscle and fat, and by reducing glucose production by the liver.1
What do human studies show?
The label summarizes open-label, randomized studies that compared insulin glargine with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes.1
In general, the reduction in HbA1c, a measure of long-term blood sugar, with insulin glargine was similar to that with NPH insulin, according to the label.1
The label presents these as insulin glargine studies; it does not describe separate efficacy trials of insulin glargine-aldy.1
What the evidence base contains
- Large randomized human trial Open-label randomized studies of insulin glargine compared with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes, summarized in the label. The largest single study enrolled 619 adults.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is insulin glargine-aldy FDA-approved?
Yes. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026.2
FDA’s approval letter licenses Langlara and states that it is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.3
The Langlara label cited here (DailyMed SPL version 5, published July 8, 2026) states the same indication and states that it is not recommended for treating diabetic ketoacidosis.1
The label has no boxed warning. It states that the product is contraindicated during episodes of low blood sugar and in people allergic to any insulin glargine product or its ingredients.1
Its warnings cover low or high blood sugar after changes in insulin treatment, low blood sugar including from medication errors, allergic reactions, low potassium, and fluid retention and heart failure when used with PPAR-gamma agonists.1
What is still unknown?
The details of FDA’s biosimilarity and interchangeability findings, which are not set out in the machine-readable pages of the approval letter reviewed here.3
How insulin glargine-aldy performed in its own clinical studies: the label’s clinical studies section describes insulin glargine studies against NPH insulin.1
Sources for this version
- 1LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026